Search Within

Pediatric Leukemia

  1. "Rachel Kobos"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (31)
Groups
  1. Center for Hematologic Malignancies (75)
  2. Pediatrics, Department of (66)
  3. Department of Medicine (52)
  4. GSK Faculty (45)
  5. Stem Cell Transplantation and Cellular Therapy Service (45)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (42)

More Groups

People
  1. Rachel Kobos (75)
  2. Nancy Kernan (40)
  3. Farid Boulad (39)
  4. Susan Prockop (39)
  5. Richard O'Reilly (36)
  6. Andromachi Scaradavou (33)

More People

Years
  1. 2025 (1)
  2. 2022 (4)
  3. 2020 (3)
  4. 2019 (2)
  5. 2018 (2)
  6. 2017 (3)

More Years

Publications
  1. Blood (19)
  2. Biology of Blood and Marrow Transplantation (14)
  3. Pediatric Blood and Cancer (13)
  4. Journal of Clinical Oncology (4)
  5. Bone Marrow Transplantation (3)
  6. Journal of Pediatric Hematology/Oncology (3)

More Publications

Publishers
  1. American Society of Hematology (20)
  2. Elsevier Inc. (14)
  3. Wiley Periodicals, Inc (13)
  4. American Society of Clinical Oncology (4)
  5. Nature Publishing Group (4)
  6. Lippincott Williams & Wilkins (3)

More Publishers

Results (75)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment of T-cell leukemia/lymphoma in children and young adults with the Memorial Sloan Kettering Cancer Center New York IIB protocol
    Journal Article

    Steinherz, P. G.; Mauguen, A.; Suser, S.; Ramaswamy, K.; Kobos, R.; Forlenza, C. J.; Shukla, N.; Trippett, T.; Wolden, S.; Steinherz, L.
    Journal of Pediatric Hematology/Oncology (2025)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Rocafiguera, A. O.; Nooka, A. K.; Rosiñol, L.; Bahlis, N. J.; Rodríguez-Otero, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K. Q.; Londhe, A.; Nair, S.; Lin, X. W.; Pei, L. X.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Krishnan, A. Y.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X. W.; Qi, K. Q.; Londhe, A.; Pei, L. X.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Bahlis, N. J.; Usmani, S. Z.; Rosiñol, L.; Krishnan, A. Y.; Nooka, A. K.; Rocafiguera, A. O.; Delforge, M.; Garfall, A. L.; van De Donk, N. W. C. J.; Rodríguez-Otero, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma
    Journal Article

    Abou-Alfa, G. K.; Mayer, R.; Venook, A. P.; O'Neill, A. F.; Beg, M. S.; LaQuaglia, M.; Kingham, P. T.; Kobos, R.; Basturk, O.; Brennan, C.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma
    Journal Article

    El Dika, I.; Mayer, R. J.; Venook, A. P.; Capanu, M.; LaQuaglia, M. P.; Kobos, R.; O'Neill, A. F.; Chou, J. F.; Ly, M.; Ang, C.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
    Journal Article

    Prockop, S.; Doubrovina, E.; Suser, S.; Heller, G.; Barker, J.; Dahi, P.; Perales, M. A.; Papadopoulos, E.; Sauter, C.; Castro-Malaspina, H.; more...
    Journal of Clinical Investigation (2020)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis
    Journal Article

    Ortiz, M. V.; Fernandez-Ledon, S.; Ramaswamy, K.; Forlenza, C. J.; Shukla, N. N.; Kobos, R.; Heaton, T. E.; LaQuaglia, M. P.; Steinherz, P. G.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save